Quality measures can be powerful tools for leveraging performance improvement, but only if they are based on reliable evidence, feasible to implement, and attributable to the providers being measured. Quality measures should also capture clinically relevant outcomes and other aspects of care that matter to patients.
Since the introduction of value-based care, quality measures have multiplied, but far too frequently, they fall short of these standards. This deficiency undermines the value of quality measurement, and not just for kidney care. In 2018, the American College of Physicians (ACP) Performance Measurement Committee determined that only 37% of the national measures being
Extraordinary times call for extraordinary measures, and at least as far as kidney care is concerned, the federal government is rising to the challenge. In the past month, the Centers for Medicare & Medicaid Services (CMS) has issued an unprecedented set of waivers to facilitate care delivery during the COVID-19 pandemic. The sweeping interim final rule the agency published March 30, 2020, provides a remarkable degree of flexibility in how providers may deliver care to patients insured through Medicare and Medicaid during the current public health emergency (1).
Equally extraordinary, nearly every one of the requests ASN put